Processa Pharmaceuticals (PCSA) Projected to Post Quarterly Earnings on Friday

Processa Pharmaceuticals (NASDAQ:PCSA) will likely be posting its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Processa Pharmaceuticals to post earnings of ($0.92) per share for the quarter.

Processa Pharmaceuticals (NASDAQ:PCSA) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.18. On average, analysts expect Processa Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Processa Pharmaceuticals Price Performance

NASDAQ:PCSA opened at $0.41 on Wednesday. The firm has a market cap of $2.17 million, a PE ratio of -0.12 and a beta of 0.75. Processa Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $3.31. The firm has a 50 day simple moving average of $0.53 and a 200-day simple moving average of $0.91.

Insider Transactions at Processa Pharmaceuticals

In other news, insider David Young purchased 124,500 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was acquired at an average cost of $0.80 per share, with a total value of $99,600.00. Following the acquisition, the insider now owns 205,405 shares in the company, valued at approximately $164,324. This trade represents a 153.88 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George K. Ng bought 87,200 shares of the stock in a transaction dated Monday, January 27th. The shares were acquired at an average price of $0.80 per share, with a total value of $69,760.00. Following the completion of the purchase, the chief executive officer now directly owns 87,200 shares of the company’s stock, valued at approximately $69,760. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 224,100 shares of company stock worth $179,280. 13.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Processa Pharmaceuticals in a report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.